Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

NCT01623167 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT01623167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01623167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 2, 2012
Completion date
November 30, 2029
Enrollment
207 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe aplastic anemia